Palb2 Mrna Expression As a Predictive and Prognostic Marker in Advanced Non-Small-Cell Lung Cancer (Nsclc) Patients (P) Treated with Cisplatin- Docetaxel Chemotherapy

Abstract Backgrounds: Astrocyte-elevated gene-1 (AEG-1) functions as an oncogene and regulates angiogenesis in non-small cell lung cancer (NSCLC). In this prospective study, we assessed the values of plasma AEG-1 mRNA expression by liquid biopsy associated with tumor response and survival in NSCLC patients treated with pemetrexed. Methods: Patients diagnosed advanced NSCLC were enrolled to be treated with pemetrexed combined platinum as first-line chemotherapy. All patients underwent blood sampling before any cancer treatment (C0) and at first response evaluation after two cycles (C2) treatments. Response to chemotherapy and survival were assessed. Plasma mRNA was extracted from peripheral blood mononuclear cell (PBMC) and quantification of RNA was performed by real-time PCR.Results: A total of 50 patients with advanced NSCLC were included and 13 of 50 patients combined with bevacizumab. In patient groups of SD (n = 13) and PD (n = 10), the plasma mRNA of AEG-1, thymidylate synthase (TS) and CK19 were elevated significantly at C2 compared to patients in treatment response group (PR, n = 27) (PR v.s. SD or PD, AEG-1: 1.22 ± 0.80 v.s. 4.51 ± 15.45, p = 0.043). NSCLC patients had elevated AEG-1 (AEG-1 ≥ 2) after 2-cycle chemotherapy had shorter PFS and OS (high AEG-1 v.s. low AEG-1, median, PFS: 5.5 v.s. 11.9 months, p = 0.021; OS: 25.9 v.s. 40.8 months, p = 0.019, respectively). In Cox regression analysis, increased plasma mRNA expression of AEG-1indicated poor prognosis in survival.Conclusion: Circulating mRNA concentration of AEG-1 could be a predictive and prognostic biomarker in NSCLC patients treated with pemetrexed. Increased expression of AEG-1 contributed to the chemoresistance and caused lung cancer progression.

Download Full-text

High mRNA Expression of LMO4, A BRCA1 Downregulator, Correlates with Better Prognosis in Erlotinib-Treated Non-Small-Cell Lung Cancer (NSCLC) Patients (P) with EGFR Mutations

Annals of Oncology ◽

10.1016/s0923-7534(20)34199-5 ◽

2012 ◽

Vol 23 ◽

pp. ix531

Author(s):

N. Karachaliou ◽

C. Costa ◽

A. Gimenez-Capitan ◽

S. Viteri ◽

A. Gasco ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Mrna Expression ◽

Cell Lung Cancer ◽

Small Cell ◽

Egfr Mutations ◽

Small Cell Lung ◽

Nsclc Patients

Download Full-text

Prognostic Roles of mRNA Expression of S100 in Non-Small-Cell Lung Cancer

BioMed Research International ◽

10.1155/2018/9815806 ◽

2018 ◽

Vol 2018 ◽

pp. 1-11 ◽

Cited By ~ 4

Author(s):

Ying Liu ◽

Jian Cui ◽

Yun-Liang Tang ◽

Liang Huang ◽

Cong-Yang Zhou ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Mrna Expression ◽

Cell Lung Cancer ◽

Prognostic Value ◽

Smoking Status ◽

S100 Protein ◽

Small Cell ◽

Small Cell Lung ◽

Nsclc Patients

The S100 protein family is involved in cancer cell invasion and metastasis, but its prognostic value in non-small-cell lung cancer (NSCLC) has not been elucidated. In the present study we investigated the prognostic role of mRNA expression of each individual S100 in NSCLC patients through the Kaplan–Meier plotter (KM plotter) database. Expression of 14 members of the S100 family correlated with overall survival (OS) for all NSCLC patients; 18 members were associated with OS in adenocarcinoma, but none were associated with OS in squamous cell carcinoma. In particular, high mRNA expression level of S100B was associated with better OS in NSCLC patients. The prognostic value of S100 according to smoking status, pathological grades, clinical stages, and chemotherapeutic treatment of NSCLC was further assessed. Although the results should be further verified in clinical trials our findings provide new insights into the prognostic roles of S100 proteins in NSCLC and might promote development of S100-targeted inhibitors for the treatment of NSCLC.

Download Full-text

COL1A1 is a potential prognostic marker and therapeutic target in non-small cell lung cancer.

Current Bioinformatics ◽

10.2174/1574893617666220114141705 ◽

2022 ◽

Vol 17 ◽

Author(s):

Boyu Pan ◽

Chen Huang ◽

Yafei Xia ◽

Cuicui Zhang ◽

Bole Li ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Prognostic Marker ◽

Cell Lung Cancer ◽

Therapeutic Target ◽

Small Cell ◽

The Cancer Genome Atlas ◽

Small Cell Lung ◽

Kegg Pathways ◽

Nsclc Patients

Background: Nowadays, non-small cell lung cancer (NSCLC) is a common and highly fatal malignancy in worldwide. Therefore, to identify the potential prognostic markers and therapeutic targets is urgent for patients. Objective: This study aims to find hub targets associated with NSCLC using multiple databases. Methods: Differentially expressed genes (DEGs) from Genome Expression Omnibus (GEO) cohorts were employed for the enrichment analyses of Gene Ontology (GO) terms and the Kyoto Encyclopedia of Genes and Genome (KEGG) pathways. Candidate key genes, filtered from the topological parameter 'Degree' and validated using the The Cancer Genome Atlas (TCGA) cohort, were analyzed for their association with clinicopathological features and prognosis of NSCLC. Meanwhile, immunohistochemical cohort analyses and biological verification were further evaluated. Results: A total of 146 DEGs were identified following data preprocessing, and a protein-protein interaction (PPI) systematic network was constructed based on them. The top ten candidate core genes were further extracted from the above PPI network by using 'Degree' value, among which COL1A1 was shown to associate with overall survival (OS) of NSCLC as determined by using the Kaplan-Meier analysis (p=0.028), and could serve as an independent prognostic factor for OS in NSCLC patients (HR, 0.814; 95% CI, 0.665-0.996; p=0.046). We then analyzed the clinical stages, PPI, mutations, potential biological functions and immune regulations of COL1A1 in NSCLC patients using multiple bioinformatics tools, including GEPIA, GeneMANIA, cBioPortal, GESA and TISIDB. Finally, we further experimentally validated the overexpression of COL1A1 in NSCLC samples, and found that inhibition of COL1A1 expression moderately sensitized NSCLC cells to cisplatin. Conclusion: Thus, our results show that COL1A1 may serve as a potential prognostic marker and therapeutic target in NSCLC.

Download Full-text

Low TIP30 Protein Expression is Associated with a High Risk of Metastasis and Poor Prognosis for Non-Small-Cell Lung Cancer

Journal of Clinical Medicine ◽

10.3390/jcm8010083 ◽

2019 ◽

Vol 8 (1) ◽

pp. 83 ◽

Cited By ~ 1

Author(s):

Chao-Ju Chen ◽

Po-An Chou ◽

Ming-Shyan Huang ◽

Yu-Peng Liu

Keyword(s):

Lung Cancer ◽

Protein Expression ◽

Small Cell Lung Cancer ◽

Mrna Expression ◽

Cell Lung Cancer ◽

Poor Prognosis ◽

Progression Free Survival ◽

Small Cell ◽

Small Cell Lung ◽

Nsclc Patients

Non-small-cell lung cancer (NSCLC) is a deadly malignancy with a high prevalence worldwide. A reliable biomarker that can predict the prognosis is required to determine the therapeutic strategy. TIP30 was first identified as a tumor suppressor. A number of mechanistic studies indicated that the downregulation of TIP30 enhances the stemness, migration and survival of NSCLC cells. However, the clinical relevance of TIP30 for the prognosis of NSCLC is unknown. From a meta-analysis of public microarray datasets, we showed the upregulation of TIP30 mRNA expression was associated with worse overall survival of NSCLC patients, which contradicted the tumor suppressive role of TIP30. It is worth noting that the TIP30 mRNA expression was not correlated with its protein expression in 15 NSCLC cell lines. The results from the immunohistochemistry of a tissue microarray showed the downregulation of the TIP30 protein expression was associated with a higher risk of metastasis. In addition, the decrease in TIP30 protein was correlated with worse overall and progression-free survival of the NSCLC patients. Multivariate analysis suggested the loss of TIP30 protein was an independent factor to predict the poor prognosis of NSCLC. Our data indicated that TIP30 protein, not mRNA, would be a potential prognostic biomarker of NSCLC.

Download Full-text